Hopfner Robert Lorne sold EVMN
November 7, 2025 · Form 4 insider transaction
Hopfner Robert Lorne sold 2,508,575 shares of Evommune, Inc., a transaction worth N/A. The trade was recorded as conversion of a derivative and disclosed on an SEC Form 4, filed 5 days after the transaction.
Footnotes
Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date.; Securities are directly held by Pivotal bioVenture Partners Fund II, L.P. ("Pivotal II"). Pivotal bioVenture Partners Fund II G.P. Ltd,, the general partner of Pivotal II, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal II are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund II G.P. Ltd, who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.